You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
安圖生物(603658.SH)取得8項醫療器械註冊證書
格隆匯 05-07 16:57

格隆匯5月7日丨安圖生物(603658.SH)公佈,公司於近日收到河南省藥品監督管理局頒發的《醫療器械註冊證》,產品名稱包括腸桿菌藥敏檢測試劑盒(比色/比濁法)、替考拉寧藥敏條(E試驗法)、替加環素藥敏條(E試驗法)、複方新諾明藥敏條(E試驗法)、頭孢噻肟藥敏條(E試驗法)、多粘菌素B藥敏條(E試驗法)、哌拉西林/他唑巴坦藥敏條(E試驗法)、米諾環素藥敏條(E試驗法)。

截至2019年12月31日,腸桿菌藥敏檢測試劑盒(比色/比濁法)累計已發生的研發投入約為154萬元;替考拉寧藥敏條(E試驗法)累計已發生的研發投入約為67萬元;替加環素藥敏條(E試驗法)累計已發生的研發投入約為57萬元;複方新諾明藥敏條(E試驗法)累計已發生的研發投入約為68萬元;頭孢噻肟藥敏條(E試驗法)累計已發生的研發投入約為66萬元;多粘菌素B藥敏條(E試驗法)累計已發生的研發投入約為56萬元;哌拉西林/他唑巴坦藥敏條(E試驗法)累計已發生的研發投入約為58萬元;米諾環素藥敏條(E試驗法)累計已發生的研發投入約為62萬元。

上述註冊證的取得,進一步豐富公司產品線,不斷滿足市場需求,是對公司現有產品的有效補充,可以逐步提高公司產品的整體競爭力。上述醫療器械註冊證的取得,短期內對公司的經營業績影響較小。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account